REVIEWS  RADIOIMMUNOTHERAPY
Guest Editor: S. J. Mather 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):297-304

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Radioimmunotherapy of prostate cancer

Smith-Jones P. M.

Nuclear Medicine Service, Department of Radiology Memorial Sloan Kettering Cancer Center New York, NY, USA

In ­recent ­years, advanc­es in the ration­al ­design of radio­phar­ma­ceu­ti­cals ­have ­helped in the intro­duc­tion of clin­i­cal­ly use­ful ther­a­peu­tic ­agents ­into the clin­ic. In par­tic­u­lar radio­lab­eled mono­clo­nal anti­bod­ies ­such as 90Y-ibri­tu­mo­mab and 131I-tos­i­tu­mo­mab ­have ­shown to be clin­i­cal­ly suc­cess­ful. More recent­ly, 177Lu has ­emerged as an attrac­tive radio­nu­clide for use in system­ic radio­ther­a­py. Like 131I, it has a long­er ­half-­live ­than 90Y ­which is ­more suit­able to the phar­ma­cok­i­net­ics of mono­clo­nal anti­bod­ies, but its chem­is­try is sim­i­lar to 90Y and, ­when inter­nal­ized, it is ­retained by the ­tumor where­as 131I can be quick­ly ­released. Metastatic pros­tate can­cer is an attrac­tive tar­get for radio­im­mu­no­ther­a­py ­since the cor­ner­stone of cur­rent ther­a­py is hor­mo­nal ther­a­py, ­which is ­only pal­li­a­tive. Prostate can­cer is ­also ­known to metas­ta­size to are­as ­such as the ­lymph ­nodes and ­bone mar­row, ­sites ­that are read­i­ly access­ible to cir­cu­lat­ing mono­clo­nal anti­bod­ies. This ­review ­will ­look at ­recent advanc­es to the treat­ment of met­a­stat­ic pros­tate can­cer ­with radio­lab­eled anti­bod­ies ­with a spe­cif­ic empha­sis on 177Lu-huJ591, a ­labeled mono­clo­nal anti­body cur­rent­ly ­under clin­i­cal eval­u­a­tion.